KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1. PMID 42492022 · J Clin Oncol · 2026-Jul-23 Trial compares two radiotherapy fractionation schedules (drug-free intervention), not a drug-containing regimen. Meets all other criteria (Phase III, randomized, human oncology, time-to-event efficacy endpoints with original results) but fails the drug intervention requirement.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial. PMID 42492015 · J Clin Oncol · 2026-Jul-23 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial. PMID 42489705 · Clin Cancer Res · 2026-Jul-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
First Measurement: Proactively Sparing the Immune System During SBRT to Early-Stage Lung Cancer-A Randomized Phase II Study. PMID 42486309 · Int J Radiat Oncol Biol Phys · 2026-Jul-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. PMID 42486133 · Lancet · 2026-Jul-22 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H S B
严格 v3 独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials. PMID 42485700 · ESMO Open · 2026-Jul-22 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Documentation. PMID 42485590 · JCO Oncol Pract · 2026-Jul-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT). PMID 42485106 · Clin Cancer Res · 2026-Jul-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Extent of Lymphadenectomy in Esophageal Cancer Surgery: Unresolved Issues in Prophylactic 3-Field Dissection. PMID 42482330 · J Chest Surg · 2026-Jul-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial. PMID 42483812 · Biomol Biomed · 2026-Jul-21 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Systematic review and adjusted indirect comparison of first-line immune checkpoint inhibitors in metastatic colorectal cancer. PMID 42481259 · Farm Hosp · 2026-Jul-21 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study. PMID 42480197 · ESMO Open · 2026-Jul-21 The record explicitly describes a Phase III randomized trial with a drug-containing intervention and primary time-to-event efficacy endpoints (PFS, OS) with hazard ratios and survival rates, meeting all eligibility criteria.
H B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 4 Figure · 7 Panel · risk visible
Preoperative single-dose systemic steroid in major head and neck surgery (J-SUPPORT 2002, PreSte-HN Study): a phase III, placebo-controlled, randomized, double-blind study. PMID 42479256 · Int J Clin Oncol · 2026-Jul-21 The study meets criteria for oncology, human, randomized, phase III, drug intervention, and original result. However, it does not include a primary or key secondary time-to-event efficacy endpoint as defined (e.g., OS, PFS, DFS, HR, Kaplan-Meier), so it is ineligible.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial. PMID 42477619 · BMC Cancer · 2026-Jul-21 The study is a randomized, drug-intervention oncology trial with a time-to-event primary endpoint (PFS). However, it is explicitly described as an 'exploratory randomized trial' and its phase is not stated as Phase III/IIIb or Phase II/III in the abstract. The eligibility criteria require explicit establishment of Phase III/IIIb or Phase II/III status, which is not met here. The study is also described as exploratory and of small sample size (n=68), further suggesting it is not a definitive trial.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Design-Outcome Concordance in Targeted-Therapy trials in Non-Small cell lung cancer: a Meta-Research study. PMID 42477876 · J Natl Cancer Inst · 2026-Jul-20 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial. PMID 42476886 · Eur Urol · 2026-Jul-20 The report is from a Phase 3 randomized trial in oncology (prostate cancer) but focuses on patient-reported outcomes (quality-of-life/safety) after radiotherapy, which is a non-drug intervention. It does not report a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, or any Kaplan-Meier/HR analysis.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Strengthening awareness and community resources for early detection of lung cancer through navigation guided screening in American Indian/Alaska Native clinics (SACRED LUNGS): Study protocol. PMID 42476254 · Contemp Clin Trials · 2026-Jul-20 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Optimizing prostate biopsy decision making - (MUSIC-screen): A 1:1 randomized controlled trial comparing micro-ultrasound versus multiparametric magnetic resonance imaging for prostate cancer diagnosis. PMID 42476253 · Contemp Clin Trials · 2026-Jul-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis. PMID 42475879 · EBioMedicine · 2026-Jul-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
First-Line Immunotherapy Versus Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis of Phase III Studies. PMID 42474934 · J Gastrointest Cancer · 2026-Jul-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors. PMID 42473802 · Future Oncol · 2026-Jul-20 The record describes a Phase III, randomized trial protocol for a novel monoclonal antibody in a rare soft tissue tumor. It is a human oncology study with a drug intervention. However, it is a protocol/registration summary without reported efficacy results, and no primary or secondary time-to-event endpoint (such as OS, PFS, DFS, or HR) is mentioned. Therefore, it does not meet the criteria for an original formal-result report of a completed trial.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial. PMID 42473780 · Arthritis Rheumatol · 2026-Jul-20 The study is a Phase 3 randomized trial of a drug (deucravacitinib) with primary results, but it is for psoriatic arthritis (not a human malignant neoplasm) and its primary/secondary endpoints are response rates (ACR20, HAQ-DI, etc.), not time-to-event outcomes like OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analyses.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Role of Locoregional Treatment in Non-Progressive De Novo Metastatic Breast Cancer under Systemic Treatment: A Randomized Controlled Trial (LTMBC). PMID 42472751 · Ann Surg Oncol · 2026-Jul-20 The record describes a randomized oncology trial with a drug-containing intervention and a primary time-to-event efficacy endpoint (OS). However, the explicit trial phase is not stated in the title, abstract, or metadata. Phase cannot be inferred from the study design or context. Therefore, eligibility is indeterminate.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Minimal incision-assisted endoscopic versus conventional open breast-conserving surgery: A multicentre randomized clinical trial. PMID 42497645 · Breast · 2026-Jul-19 The study is a phase III randomized controlled trial in oncology (breast cancer), but it compares surgical techniques (minimal incision-assisted endoscopic vs. conventional open breast-conserving surgery) and does not involve a drug-containing intervention. The primary and secondary endpoints are patient-reported outcomes (scar satisfaction, QoL) and surgical metrics, not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study. PMID 42472670 · Am J Hematol · 2026-Jul-19 The study is a randomized Phase III trial with a drug intervention (eltrombopag) and time-to-event endpoints (OS, DFS, EFS), but it is for severe aplastic anemia, a non-oncology hematologic disorder, not a malignant neoplasm.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials. PMID 41663033 · Int J Radiat Oncol Biol Phys · 2026-Jul-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
International analysis of reimbursement rates and clinical benefit of genitourinary cancer drugs across Canada, France, England, Wales, Scotland, Spain, Italy, and Portugal. PMID 41653082 · Int J Cancer · 2026-Jul-15 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Randomized, multicenter phase 3 study evaluating radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma patients achieving CR/PR after induction chemotherapy. PMID 42436536 · BMC Med · 2026-Jul-11 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Dosimetric analysis of post-radiotherapy sexual dysfunction in patients receiving definitive stereotactic body radiotherapy (SBRT) for prostate cancer: a secondary analysis of MIRAGE. PMID 42435817 · Radiother Oncol · 2026-Jul-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of the tree sublingual immunotherapy tablet in the subpopulation of Canadian children with allergic rhinitis and/or conjunctivitis: phase III trial results. PMID 42432760 · Allergy Asthma Clin Immunol · 2026-Jul-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Glucagon-like peptide-1 agonists in Parkinson's disease: a meta-analysis. PMID 42432163 · Neurol Sci · 2026-Jul-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial. PMID 42435772 · Lancet Oncol · 2026-Jul-10 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H S B
严格 v3 独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Phased rehabilitation nursing improves hip function, reduces complications, and enhances quality of life following total hip arthroplasty: A prospective quasi-experimental cohort study. PMID 42432916 · Medicine (Baltimore) · 2026-Jul-10 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ultrahypofractionation of localized prostate cancer-an updated statement of the prostate cancer working group of the German Society of Radiation Oncology (DEGRO). PMID 42432214 · Strahlenther Onkol · 2026-Jul-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Acute toxicity and quality of life with stereotactic body radiotherapy versus conventional fractionated intensity-modulated radiotherapy to the prostate and pelvis in high-risk prostate cancer (SRAM): A randomized phase II trial. PMID 42431329 · Int J Radiat Oncol Biol Phys · 2026-Jul-10 The trial is a randomized Phase II oncology study in humans, but it fails the eligibility criteria because it is not Phase III/IIIb or a definitive Phase II/III, its primary endpoint is acute toxicity (not a time-to-event efficacy endpoint), and it does not test a drug-containing intervention as the experimental arm.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431. PMID 42431264 · J Thorac Oncol · 2026-Jul-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L). PMID 42431263 · J Thorac Oncol · 2026-Jul-10 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation. PMID 42372729 · Med · 2026-Jul-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer. PMID 42492306 · Eur J Cancer · 2026-Jul-09 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group. PMID 42426976 · Aliment Pharmacol Ther · 2026-Jul-09 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effectiveness and safety of intravitreal faricimab for macular oedema secondary to retinal vein occlusion: a systematic review and meta-analysis. PMID 42426919 · Int J Retina Vitreous · 2026-Jul-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Re: Murthy V, Maitre P, Pal M, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-invasive Bladder Cancer. J Clin Oncol. In press. http://dx.doi.org/10.1200/JCO-25-02093. PMID 42425857 · Eur Urol · 2026-Jul-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trial. PMID 42425800 · Ann Rheum Dis · 2026-Jul-09 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial. PMID 42425122 · Lancet · 2026-Jul-09 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial. PMID 42425121 · Lancet · 2026-Jul-09 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial. PMID 42424063 · JAMA Oncol · 2026-Jul-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Secondary Prophylaxis of Recurrent Clostridioides difficile Infections During Systemic Antibiotics with Vancomycin (SPORES-V): study protocol for a randomized controlled trial. PMID 42421140 · Trials · 2026-Jul-09 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine Administered 24 Months Following a Primary Dose in Adults ≥60 Years of Age. PMID 42419724 · J Infect Dis · 2026-Jul-09 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial. PMID 42424856 · Vaccine · 2026-Jul-08 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rationale, design and methods of the Cul-CM study: a protocol for cultural adaptation of contingency management in adults with stimulant use disorder. PMID 42419893 · BMJ Open · 2026-Jul-08 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -